Linagliptin attenuates diabetes-induced cerebral pathological neovascularization in a blood glucose-independent manner

Potential role of ET-1

Mohammed Abdelsaid, Raeonda Williams, Trevor Hardigan, Adviye Ergul

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims We have shown that glycemic control with metformin or endothelin-1 (ET-1) inhibition with bosentan prevents and restores diabetes-mediated cerebral pathological remodeling and neovascularization. Our recent data suggest that linagliptin, a member of the dipeptidyl peptidase-4 inhibitor class of glucose-lowering agents, prevents cerebrovascular remodeling and dysfunction independent of its blood glucose lowering effects. We hypothesized that linagliptin prevents pathological neovascularization via the modulation of the ET-1 system. Materials and methods 24-week old diabetic Goto-Kakizaki and nondiabetic Wistar rats were treated for 4 weeks with either vehicle chow or chow containing 166 mg/kg linagliptin. At termination, FITC-dextran was injected to visualize the vasculature. Brain sections were imaged by confocal microscopy for vascular density, tortuosity, vascular volume, and surface in both the cortex and striatum. Retinal acellular capillary formation was measured. Brain microvascular endothelial cells (BMVEC) isolated from control or diabetic rats were treated with linagliptin with or without ET-1 dual receptor antagonist and tested for angiogenic properties with cell migration and tube formation assays. Key finding Linagliptin reduced all indices of cerebral neovascularization compared with control rats. In vitro, linagliptin normalized the augmented angiogenic properties of BMVECs isolated from diabetic animals and bosentan reversed this response. Cells from diabetic animals had higher ET-1 and less ETB receptors than in control cells. Linagliptin significantly decreased ET-1 levels and increased ETB receptors. Significance ET system contributes to pathological neovascularization in diabetes as evidenced by restoration of functional angiogenesis by bosentan treatment and prevention of linagliptin-mediated improvement of angiogenesis in the in vitro model.

Original languageEnglish (US)
Pages (from-to)83-89
Number of pages7
JournalLife sciences
Volume159
DOIs
StatePublished - Aug 15 2016

Fingerprint

Pathologic Neovascularization
Endothelin-1
Medical problems
Blood Glucose
Blood Vessels
Rats
Brain
Animals
Rat control
Dipeptidyl-Peptidase IV Inhibitors
Endothelin A Receptors
Angiogenesis Inhibitors
Linagliptin
Confocal microscopy
Metformin
Endothelial cells
Confocal Microscopy
Restoration
Cell Movement
Wistar Rats

Keywords

  • Diabetes
  • Endothelin
  • Linagliptin and neovascularization

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Linagliptin attenuates diabetes-induced cerebral pathological neovascularization in a blood glucose-independent manner : Potential role of ET-1. / Abdelsaid, Mohammed; Williams, Raeonda; Hardigan, Trevor; Ergul, Adviye.

In: Life sciences, Vol. 159, 15.08.2016, p. 83-89.

Research output: Contribution to journalArticle

Abdelsaid, Mohammed ; Williams, Raeonda ; Hardigan, Trevor ; Ergul, Adviye. / Linagliptin attenuates diabetes-induced cerebral pathological neovascularization in a blood glucose-independent manner : Potential role of ET-1. In: Life sciences. 2016 ; Vol. 159. pp. 83-89.
@article{e90baa0bcba443e5898fd9251fbf7284,
title = "Linagliptin attenuates diabetes-induced cerebral pathological neovascularization in a blood glucose-independent manner: Potential role of ET-1",
abstract = "Aims We have shown that glycemic control with metformin or endothelin-1 (ET-1) inhibition with bosentan prevents and restores diabetes-mediated cerebral pathological remodeling and neovascularization. Our recent data suggest that linagliptin, a member of the dipeptidyl peptidase-4 inhibitor class of glucose-lowering agents, prevents cerebrovascular remodeling and dysfunction independent of its blood glucose lowering effects. We hypothesized that linagliptin prevents pathological neovascularization via the modulation of the ET-1 system. Materials and methods 24-week old diabetic Goto-Kakizaki and nondiabetic Wistar rats were treated for 4 weeks with either vehicle chow or chow containing 166 mg/kg linagliptin. At termination, FITC-dextran was injected to visualize the vasculature. Brain sections were imaged by confocal microscopy for vascular density, tortuosity, vascular volume, and surface in both the cortex and striatum. Retinal acellular capillary formation was measured. Brain microvascular endothelial cells (BMVEC) isolated from control or diabetic rats were treated with linagliptin with or without ET-1 dual receptor antagonist and tested for angiogenic properties with cell migration and tube formation assays. Key finding Linagliptin reduced all indices of cerebral neovascularization compared with control rats. In vitro, linagliptin normalized the augmented angiogenic properties of BMVECs isolated from diabetic animals and bosentan reversed this response. Cells from diabetic animals had higher ET-1 and less ETB receptors than in control cells. Linagliptin significantly decreased ET-1 levels and increased ETB receptors. Significance ET system contributes to pathological neovascularization in diabetes as evidenced by restoration of functional angiogenesis by bosentan treatment and prevention of linagliptin-mediated improvement of angiogenesis in the in vitro model.",
keywords = "Diabetes, Endothelin, Linagliptin and neovascularization",
author = "Mohammed Abdelsaid and Raeonda Williams and Trevor Hardigan and Adviye Ergul",
year = "2016",
month = "8",
day = "15",
doi = "10.1016/j.lfs.2015.11.026",
language = "English (US)",
volume = "159",
pages = "83--89",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Linagliptin attenuates diabetes-induced cerebral pathological neovascularization in a blood glucose-independent manner

T2 - Potential role of ET-1

AU - Abdelsaid, Mohammed

AU - Williams, Raeonda

AU - Hardigan, Trevor

AU - Ergul, Adviye

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Aims We have shown that glycemic control with metformin or endothelin-1 (ET-1) inhibition with bosentan prevents and restores diabetes-mediated cerebral pathological remodeling and neovascularization. Our recent data suggest that linagliptin, a member of the dipeptidyl peptidase-4 inhibitor class of glucose-lowering agents, prevents cerebrovascular remodeling and dysfunction independent of its blood glucose lowering effects. We hypothesized that linagliptin prevents pathological neovascularization via the modulation of the ET-1 system. Materials and methods 24-week old diabetic Goto-Kakizaki and nondiabetic Wistar rats were treated for 4 weeks with either vehicle chow or chow containing 166 mg/kg linagliptin. At termination, FITC-dextran was injected to visualize the vasculature. Brain sections were imaged by confocal microscopy for vascular density, tortuosity, vascular volume, and surface in both the cortex and striatum. Retinal acellular capillary formation was measured. Brain microvascular endothelial cells (BMVEC) isolated from control or diabetic rats were treated with linagliptin with or without ET-1 dual receptor antagonist and tested for angiogenic properties with cell migration and tube formation assays. Key finding Linagliptin reduced all indices of cerebral neovascularization compared with control rats. In vitro, linagliptin normalized the augmented angiogenic properties of BMVECs isolated from diabetic animals and bosentan reversed this response. Cells from diabetic animals had higher ET-1 and less ETB receptors than in control cells. Linagliptin significantly decreased ET-1 levels and increased ETB receptors. Significance ET system contributes to pathological neovascularization in diabetes as evidenced by restoration of functional angiogenesis by bosentan treatment and prevention of linagliptin-mediated improvement of angiogenesis in the in vitro model.

AB - Aims We have shown that glycemic control with metformin or endothelin-1 (ET-1) inhibition with bosentan prevents and restores diabetes-mediated cerebral pathological remodeling and neovascularization. Our recent data suggest that linagliptin, a member of the dipeptidyl peptidase-4 inhibitor class of glucose-lowering agents, prevents cerebrovascular remodeling and dysfunction independent of its blood glucose lowering effects. We hypothesized that linagliptin prevents pathological neovascularization via the modulation of the ET-1 system. Materials and methods 24-week old diabetic Goto-Kakizaki and nondiabetic Wistar rats were treated for 4 weeks with either vehicle chow or chow containing 166 mg/kg linagliptin. At termination, FITC-dextran was injected to visualize the vasculature. Brain sections were imaged by confocal microscopy for vascular density, tortuosity, vascular volume, and surface in both the cortex and striatum. Retinal acellular capillary formation was measured. Brain microvascular endothelial cells (BMVEC) isolated from control or diabetic rats were treated with linagliptin with or without ET-1 dual receptor antagonist and tested for angiogenic properties with cell migration and tube formation assays. Key finding Linagliptin reduced all indices of cerebral neovascularization compared with control rats. In vitro, linagliptin normalized the augmented angiogenic properties of BMVECs isolated from diabetic animals and bosentan reversed this response. Cells from diabetic animals had higher ET-1 and less ETB receptors than in control cells. Linagliptin significantly decreased ET-1 levels and increased ETB receptors. Significance ET system contributes to pathological neovascularization in diabetes as evidenced by restoration of functional angiogenesis by bosentan treatment and prevention of linagliptin-mediated improvement of angiogenesis in the in vitro model.

KW - Diabetes

KW - Endothelin

KW - Linagliptin and neovascularization

UR - http://www.scopus.com/inward/record.url?scp=84949669381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949669381&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2015.11.026

DO - 10.1016/j.lfs.2015.11.026

M3 - Article

VL - 159

SP - 83

EP - 89

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -